Personalizing induction therapy in kidney transplantation

Nature Reviews Nephrology

Volumn 5, Issue 11, 2009, Pages 619-620

  Aull, Meredith J ^a   Suthanthiran, Manikkam ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CORTICOSTEROID; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; BACTERIAL INFECTION; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; TREATMENT INDICATION; TREATMENT PLANNING; GRAFT REJECTION; INCIDENCE; METHODOLOGY; NOTE; PERSONALIZED MEDICINE;

ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INDIVIDUALIZED MEDICINE; KIDNEY TRANSPLANTATION; RISK FACTORS;

EID: 70350515660     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.164     Document Type: Short Survey

References (6)

1. Us Department of Health and Human services 2007 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1997-2006 [online], http:// www.ustransplant.org/annual-reports/current/ (2009).
2. webster, A. C., Playford, E. G., Higgins, G., Chapman, J. R. & Craig, J. C. interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 77, 166-176 (2004).
3. Noël, C. et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J. Am. Soc. Nephrol. 20, 1385-1392 (2009).
4. Brennan, D. C., Daller, J. A., Lake, K. D., Cibrik, D. & Del Castillo, D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N. Engl. J. Med. 355, 1967-1977 (2006).
5. Patlolla, V., Zhong, X., Reed, G. W. & Mandelbrot, D. A. efficacy of anti-iL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am. J. Transplant. 7, 1832-1842 (2007).
6. Mulgaonkar, S. et al. Continuing 24 month results of a multicenter, randomized trial comparing three induction agents (alemtuzumab, thymoglobulin, and basiliximab) with tacrolimus, mycophenolate mofetil, and a rapid steroid withdrawal in renal transplantation [abstract]. Am. J. Transplant. 9 (Suppl. 2), 282 (2009).